CSO Jane Gross to resign Sept 14, 2021; will consult through Dec 31, 2021

Aptevo Therapeutics Inc.

Jane Gross resigns as Chief Scientific Officer effective Sept 14, 2021; transitions to consultant through Dec 31, 2021.
Receives lump-sum $166,000 cash payment by Jan 7, 2022; hourly rate for transition hours beyond stated limit.
Vested stock options exercisable for 90 days from Jan 1, 2022.
Non-compete and non-solicitation obligations for 12 months following last day of employment.
Company has commenced search for a new Chief Scientific Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jane Gross

Chief Scientific Officer

APVO · Aptevo Therapeutics Inc.

Effective: 2021-09-14
Filed: August 27, 2021, 7:59 PM ET

On August 25, 2021, Jane Gross (“Gross”) resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. (the “Company”) effective September 14, 2021 (“Separation Date”)

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jane Gross resigned as Chief Scientific Officer at Aptevo Therapeutics Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On August 25, 2021, Jane Gross (“Gross”) resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. (the “Company”) effective September 14, 2021 (“Separation Date”)

View on SEC.gov

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-046031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.